Table 2.
The associated treatment progress of DKD by targeting ferroptosis
| Treatments | Related signaling pathways | Mechanisms | Experimental models | References |
|---|---|---|---|---|
| N.A. | N.A. | Decrease in SLC7A11 and GPX4 expression | DKD patient kidney tubules | 83 |
| N.A. | N.A. | Increase in ferritin, LDH, ACSL4, PTGS2 and NOX1 expression; Decrease in GPX4 expression |
DKD patient serum | 86 |
| Ferroastatin-1 | Upregulate p53 and nuclear Nrf2 expression | Increase in SLC7A11 and GPX4 expression; Decrease in FTH1 expression |
STZ-induced diabetic mice; db/db mice; TGF-β1-stimulated NRK-52E cells |
83 |
| Ferroastatin-1 | Downregulate HIF-1α/HO-1 pathway | Increase in GPX4, GSH-Px, CAT and SOD expression; Decrease in ferritin, transferrin, MDA and ROS expression |
db/db mice | 136 |
| Ferroastatin-1 | N.A. | Increase in GPX4 expression; Decrease in ZIP14 expression |
STZ-induced diabetic rats; High glucose-treated HK-2 cells |
145 |
| Deferoxamine | N.A. | Increased in GPX4, FTH1 and SLC7A11 expression; Decreased in ACSL4 and TFR1 expression |
High glucose-treated HK-2 cells | 161 |
| Rosiglitazone | Downregulate IL-6 and TNF-α expression | Increase in GPX4 expression; Decrease in PTGS2 and ASCL4 expression |
STZ-induced diabetic mice; db/db mice; High glucose-treated NRK-52E cells; High glucose-treated HK-2 cells |
68 |
| Rosiglitazone | Regulate VEGF/Akt/ERK pathway | Increase in GPX4, SLC7A11 and SLC3A2 expression; Decrease in TFR1 expression |
STZ- and HFD- induced diabetic mice; High glucose-treated NRK-52E cells |
162 |
| Fenofibrate | Upregulate Nrf2 expression | Increase in GPX4, SLC7A11 and FTH1 expression; Decrease in TFR1 expression |
STZ-induced diabetic mice; High glucose-treated HK-2 cells |
88 |
| Dapagliflozin | Upregulate FPN expression | Increase in GPX4 and ASCL4 expression | STZ- and HFD- induced diabetic mice; High glucose-treated HK-2 cells |
163 |
| Calycosin. | N.A. | Increased in GPX4 expression; Decreased in NCOA4 expression |
db/db mice; High glucose-treated HK-2 cells |
164 |
| Glabridin | Regulate VEGF/Akt/ERK pathway | Increase in GPX4, SLC7A11 and SLC3A2 expression; Decrease in TFR1 expression |
STZ- and HFD- induced diabetic mice; High glucose-treated NRK-52E cells |
162 |
| Platycodin D | N.A. | Increased in GPX4, FTH1 and SLC7A11expression; Decreased in ACSL4 and TFR1 expression |
High glucose-treated HK-2 cells | 161 |
| Schisandrin A | Upregulate AdipoR1/AMPK pathway; Downregulate TXNIP/NLRP3 pathway |
Increased in GPX4, SOD, CAT and GSH-Px expression; Decreased in LDH expression |
STZ- and HFD- induced diabetic mice; High glucose-treated HRGEnCs |
165 |
| Umbelliferone | Upregulate Nrf2/HO-1 pathway | Increase in GPX4 expression; Decrease in ACSL4 expression | High glucose-treated HK-2 cells; db/db mice |
166 |
| NAC combined with insulin | Upregulate SIRT3 expression | Increase in GPX4 and SLC7A11 expression; Decrease in ferritin and TFR1 expression and the acetylation level of SOD2 |
STZ- and ALX- induced diabetic Beagles; High glucose-treated MDCK cells |
149 |
| Germacrone | Regulate mmu_circRNA_0000309/miR-188-3p pathway | Increase in GPX4 and FTH1 expression; Decrease in COX4, ACSL4 and NOX1 expression |
db/db mice; High glucose-treated MPC5 |
152 |
| Overexpression of Sp1 | Upregulate Prdx6 expression | Increase in SLC7A11 and GPX4 expression | STZ-induced diabetic mice; High glucose-treated MPC5 |
84 |
| Knockdown of Salusin‑β | Upregulate Nrf2 expression | Increase in GPX4, SLC7A11 and FTH1 expression; Decreased TFR1 expression |
High glucose-treated HK‑2 cells | 157 |
| Knockdown of HMGB1 | Downregulate TLR4/NF-κB pathway Upregulate Nrf2 expression |
Increase in GPX4 expression; Decrease in ferritin, LDH, ACSL4, PTGS2 and NOX1 expression |
High glucose-treated SV40-MES13 cells | 86 |
| Knockdown of Circ_ASAP2 | Regulate miR‑770‑5p/SOX2/SLC7A11 pathway | Increase in MDA expression; Decrease in GPX4, SOD, CAT and GSH-Px expression |
STZ- and HFD- induced diabetic mice; High glucose-treated HK-2 cells |
153 |
N.A.: Not applicable.